Changes in functional status in patients with COPD during therapy with Spiolto® Respimat® (Ellacto study)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS28719
• Study ID:
  28720
• Official title and acronym:
  Changes in functional status in patients with COPD during therapy with Spiolto® Respimat® (Ellacto study)
• DARWIN EU® study:
  No
• Study countries:
  Greece
• Study description:
  This study aims to investigate functional status of COPD patients treated with Spiolto ® Respimat® by means of the CCQ questionnaire, more specifically by its ‘functional status’ subdomain (CCQ-4).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Metropolitan Hospital

Study timelines

Date when funding contract was signed

Planned:30/11/2017

Study start date

Planned:01/03/2018

Actual:19/03/2018

Date of final study report

Planned:30/05/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

BOEHRINGER INGELHEIM ELLAS SA

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable